Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Interest Expenses (2017)

Crinetics Pharmaceuticals has reported Interest Expenses over the past 1 years, most recently at $1000.0 for Q4 2017.

  • Quarterly results put Interest Expenses at $1000.0 for Q4 2017, changed N/A from a year ago — trailing twelve months through Sep 2018 was $1000.0 (changed N/A YoY), and the annual figure for FY2017 was $8000.0, down 27.27%.
  • Interest Expenses for Q4 2017 was $1000.0 at Crinetics Pharmaceuticals, down from $2000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for CRNX hit a ceiling of $3000.0 in Q2 2017 and a floor of $1000.0 in Q4 2017.